Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28575852 | 0.87 | SLC22A12 (0.62) | L3MBTL1MAPK1LMNACHRM1POLB | |
| SCHEMBL5428199 | 0.86 | NR1I2 (0.54) | L3MBTL1MAPK1LMNACHRM1POLB | |
| SCHEMBL1606606 | 0.86 | LMNA (0.80) | L3MBTL1MAPK1LMNACHRM1ADORA1 | |
| SCHEMBL31693410 | 0.85 | TP53 (0.67) | L3MBTL1MAPK1LMNACHRM1POLB | |
| SCHEMBL28222415 | 0.83 | LMNA (0.68) | L3MBTL1MAPK1LMNACHRM1POLB | |
| SCHEMBL13621801 | 0.83 | LMNA (0.68) | L3MBTL1MAPK1LMNACHRM1POLB | |
| SCHEMBL30497877 | 0.82 | POLB (0.78) | L3MBTL1MAPK1LMNACHRM1POLB | |
| SCHEMBL28397328 | 0.82 | L3MBTL1 (1.00) | L3MBTL1MAPK1LMNAPOLBADORA1 | |
| SCHEMBL16341399 | 0.82 | LMNA (0.73) | L3MBTL1MAPK1LMNACHRM1 | |
| SCHEMBL3429738 | 0.81 | CHRM1 (0.65) | L3MBTL1MAPK1LMNACHRM1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883841-B2 | Oncogenic ras-specific cytotoxic compound and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-11-11 | — | — | US | disclosed |
| EP-1956910-B1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | UNIV TEXAS (US) | 2014-09-17 | — | — | EP | disclosed |
| CN-101360422-B | Oncogenic Ras-specific cytotoxic compound and methods of usethereof | UNIV TEXAS | 2013-10-23 | — | — | CN | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-11-19 | — | — | US | disclosed |
| CN-101360422-A | Oncogenic ras-specific cytotoxic compound and methods of usethereof | UNIV TEXAS (US) | 2009-02-04 | — | — | CN | disclosed |
| EP-1956910-A2 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | The Board of Regents of The University of Texas System (US) | 2008-08-20 | — | — | EP | disclosed |
| WO-2007062399-A2 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286847-A1 | ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | L3MBTL1 452/4885MAPK1 284/4885LMNA 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.